$80.75
0.87% yesterday
Nasdaq, Dec 24, 08:26 pm CET
ISIN
US6047491013
Symbol
MIRM

Mirum Pharmaceuticals Inc Stock price

$80.75
+8.55 11.84% 1M
+29.64 57.99% 6M
+39.40 95.28% YTD
+38.58 91.49% 1Y
+62.51 342.71% 3Y
+62.50 342.47% 5Y
+67.54 511.28% 10Y
+67.54 511.28% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.70 0.87%
ISIN
US6047491013
Symbol
MIRM
Industry

Key metrics

Basic
Market capitalization
$4.2b
Enterprise Value
$4.1b
Net debt
positive
Cash
$375.6m
Shares outstanding
51.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.8 | 8.1
EV/Sales
8.7 | 7.9
EV/FCF
92.5
P/B
14.3
Financial Health
Equity Ratio
33.6%
Return on Equity
-39.0%
ROCE
-6.7%
ROIC
-
Debt/Equity
1.1
Financials (TTM | estimate)
Revenue
$471.8m | $518.1m
EBITDA
$-17.4m | $-16.1m
EBIT
$-41.6m | $-20.7m
Net Income
$-41.6m | $-20.2m
Free Cash Flow
$44.4m
Growth (TTM | estimate)
Revenue
53.7% | 53.8%
EBITDA
76.0% | 74.9%
EBIT
56.7% | 76.4%
Net Income
58.3% | 77.0%
Free Cash Flow
260.9%
Margin (TTM | estimate)
Gross
79.9%
EBITDA
-3.7% | -3.1%
EBIT
-8.8%
Net
-8.8% | -3.9%
Free Cash Flow
9.4%
More
EPS
$-0.7
FCF per Share
$0.9
Short interest
14.5%
Employees
322
Rev per Employee
$1.1m
Show more

Is Mirum Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Mirum Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Mirum Pharmaceuticals Inc forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Mirum Pharmaceuticals Inc forecast:

Buy
94%
Hold
6%

Financial data from Mirum Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
472 472
54% 54%
100%
- Direct Costs 95 95
13% 13%
20%
377 377
69% 69%
80%
- Selling and Administrative Expenses 240 240
25% 25%
51%
- Research and Development Expense 179 179
40% 40%
38%
-17 -17
76% 76%
-4%
- Depreciation and Amortization 24 24
3% 3%
5%
EBIT (Operating Income) EBIT -42 -42
57% 57%
-9%
Net Profit -42 -42
58% 58%
-9%

In millions USD.

Don't miss a Thing! We will send you all news about Mirum Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mirum Pharmaceuticals Inc Stock News

Positive
Investors Business Daily
2 days ago
This biotech stock reached an all-time high and is in a buy zone. The company makes drugs for rare diseases.
Positive
Seeking Alpha
3 days ago
Mirum Pharmaceuticals, Inc. retains a Buy rating, supported by positive interim analyses for VOLIXIBAT in both PBC [VANTAGE] and PSC [VISTAS] phase 2b trials. Key catalysts include VISTAS topline data in Q2 2026, VANTAGE topline data in H1 2027, and phase 3 EXPAND enrollment completion in 2026. Company strengthened its balance sheet with $200M gross proceeds from Bluejay Therapeutics acquisitio...
Neutral
Business Wire
6 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX.
More Mirum Pharmaceuticals Inc News

Company Profile

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

Head office United States
CEO Christopher Peetz
Employees 322
Founded 2018
Website mirumpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today